180 / Safar V, Dupuis J, Itti E, Jardin F, Fruchart C, Bardet S, Véra P, Copie-Bergman C, Rahmouni A, Tilly H, Meignan M, Haioun C. Interim[18F]Fluorodeoxyglucose Positron Emission Tomography Scan in Diffuse Large B-CellLymphoma Treated With Anthracycline-Based Chemotherapy Plus Rituximab. J Clin Oncol. 2011 Dec 12. http://jco.ascopubs.org/ 179 / Récher C, Coiffier B, Haioun C, Molina TJ, Fermé C, Casasnovas O, Thiéblemont C, Bosly A, Laurent G, Morschhauser F, Ghesquières H, Jardin F, Bologna S, Fruchart C, Corront B, Gabarre J, Bonnet C, Janvier M, Canioni D, Jais JP, Salles G, Tilly H; Groupe d'Etude des Lymphomes de l'Adulte. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. Lancet. 2011 Nov 26;378(9806):1858-67. http://www.thelancet.com/ 178 / Vidal L, Gafter-Gvili A, Salles G, Dreyling MH, Ghielmini M, Hsu Schmitz SF, Pettengell R, Witzens-Harig M, Shpilberg O. Rituximab Maintenance for the Treatment of Patients With Follicular Lymphoma: An Updated Systematic Review and Meta-analysis of Randomized Trials. J Natl Cancer Inst. 2011 Dec 7;103(23):1799-806. http://jnci.oxfordjournals.org 177 / Thieblemont C, Briere J, Mounier N, Voelker HU, Cuccuini W, Hirchaud E, Rosenwald A, Jack A, Sundstrom C, Cogliatti S, Trougouboff P, Boudova L, Ysebaert L, Soulier J, Chevalier C, Bron D, Schmitz N, Gaulard P, Houlgatte R, Gisselbrecht C. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study. J Clin Oncol. 2011 Nov 1;29(31):4079-87. http://jco.ascopubs.org/ 176 / Trotman J, Fournier M, Lamy T, Seymour JF, Sonet A, Janikova A, Shpilberg O, Gyan E, Tilly H, Estell J, Forsyth C, Decaudin D, Fabiani B, Gabarre J, Salles B, Van Den Neste E, Canioni D, Garin E, Fulham M, Vander Borght T, Salles G. Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants. J Clin Oncol. 2011 Aug 10;29(23):3194-200. http://jco.ascopubs.org/ 175 / Decaudin D, Mounier N, Tilly H, Ribrag V, Ghesquières H, Bouabdallah K, Morschhauser F, Coiffier B, Le Gouill S, Bologna S, Delarue R, Huynh A, Bosly A, Brière J, Gisselbrecht C. (90)Y ibritumomab tiuxetan (Zevalin) combined with BEAM(Z -BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory low-grade CD20-positive B-cell lymphoma. A GELA phase II prospective study. Clin Lymphoma Myeloma Leuk. 2011 Apr;11(2):212-8. http://www.clinical-lymphoma-myeloma-leukemia.com 174 / Fitoussi O, Belhadj K, Mounier N, Parrens M, Tilly H, Salles G, Feugier P, Ferme C, Ysebaert L, Gabarre J, Herbrecht R, Janvier M, Van Den Neste E, Morschhauser F, Casasnovas O, Ghesquieres H, Anglaret B, Brechignac S, Haioun C, Gisselbrecht C. Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA. Haematologica. 2011 Aug;96(8):1136-43. http://www.haematologica.org 173 / Salles G, de Jong D, Xie W, Rosenwald A, Chhanabhai M, Gaulard P, Klapper W, Calaminici M, Sander B, Thorns C, Campo E, Molina T, Lee A, Pfreundschuh M, Horning S, Lister A, Sehn LH, Raemaekers J, Hagenbeek A, Gascoyne RD, Weller E. Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium. Blood. 2011 Jun 30;117(26):7070-8. http://bloodjournal.hematologylibrary.org/ 172 / Casasnovas RO, Meignan M, Berriolo-Riedinger A, Bardet S, Julian A, Thieblemont C, Vera P, Bologna S, Brière J, Jais JP, Haioun C, Coiffier B, Morschhauser F; Groupe d'étude des lymphomes de l'adulte (GELA). SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. Blood. 2011 Jul 7;118(1):37-43. http://bloodjournal.hematologylibrary.org/ 171 / Le Gouill S, De Guibert S, Planche L, Brice P, Dupuis J, Cartron G, Van Hoof A, Casasnovas O, Gyan E, Tilly H, Fruchart C, Deconinck E, Fitoussi O, Gastaud L, Delwail V, Gabarre J, Gressin R, Blanc M, Foussard C, Salles G; GELA and GOELAMS. Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study. Haematologica. 2011 Aug;96(8):1128-35. http://www.haematologica.org/ 170 / Peyrade F, Jardin F, Thieblemont C, Thyss A, Emile JF, Castaigne S, Coiffier B, Haioun C, Bologna S, Fitoussi O, Lepeu G, Fruchart C, Bordessoule D, Blanc M, Delarue R, Janvier M, Salles B, André M, Fournier M, Gaulard P, Tilly H; Groupe d'Etude des Lymphomes de l'Adulte (GELA) investigators. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2011 May;12(5):460-8. http://www.thelancet.com/ 169 / Heutte N, Haioun C, Feugier P, Coiffier B, Tilly H, Ferme C, Gabarre J, Morschhauser F, Gisselbrecht C, Mounier N; Groupe d'Etude des Lymphomes de l'Adulte. Quality of life in 269 patients with poor-risk diffuse large B-cell lymphoma treated with rituximab versus observation after autologous stem cell transplant. Leuk Lymphoma. 2011 Jul;52(7):1239-48. http://www.ncbi.nlm.nih.gov/pubmed?term=Leuk%20Lym 168 / Salles G, Seymour JF, Offner F, López-Guillermo A, Belada D, Xerri L, Feugier P, Bouabdallah R, Catalano JV, Brice P, Caballero D, Haioun C, Pedersen LM, Delmer A, Simpson D, Leppa S, Soubeyran P, Hagenbeek A, Casasnovas O, Intragumtornchai T, Fermé C, da Silva MG, Sebban C, Lister A, Estell JA, Milone G, Sonet A, Mendila M, Coiffier B, Tilly H. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011 Jan 1;377(9759):42-51. http://www.thelancet.com/ 167 / Mounier N, Gisselbrecht C. Stem cell transplantation for diffuse large B-cell lymphoma patients in the rituximab era. Curr Opin Oncol. 2011 Mar;23(2):209-13. http://journals.lww.com/co-oncology/pages/default. 166 / Jaccard A, Gachard N, Marin B, Rogez S, Audrain M, Suarez F, Tilly H, Morschhauser F, Thieblemont C, Ysebaert L, Devidas A, Petit B, de Leval L, Gaulard P, Feuillard J, Bordessoule D, Hermine O; GELA and GOELAMS Intergroup. Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. Blood. 2011 Feb 10;117(6):1834-9. http://bloodjournal.hematologylibrary.org/ 165 / Morel P, Munck JN, Coiffier B, Gisselbrecht C, Ranta D, Bosly A, Tilly H, Quesnel B, Thyss A, Mounier N, Brière J, Molina T, Reyes F; Groupe d'Etude de Lymphomes des l'Adulte (GELA). Comparison of two high-dose cyclophosphamide, doxorubicin, vincristine, and prednisone derived regimens in patients aged under 60 years with low-intermediate risk aggressive lymphoma: a final analysis of the multicenter LNH93-2 protocol. Leuk Lymphoma. 2010 Sep;51(9):1668-77. http://www.ncbi.nlm.nih.gov/pubmed/20807094 164 / Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, Bosly A, Ketterer N, Shpilberg O, Hagberg H, Ma D, Brière J, Moskowitz CH, Schmitz N. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010 Sep 20;28(27):4184-90. http://jco.ascopubs.org/ 163 / Morschhauser F, Mounier N, Sebban C, Brice P, Solal-Celigny P, Tilly H, Feugier P, Fermé C, Copin MC, Lamy T. Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naive, recurrent/refractory follicular non-Hodgkin lymphoma with high tumor burden: a multicenter phase 2 trial by the Groupe d'Etude des Lymphomes de l'Adulte (GELA) and Groupe Ouest Est des Leucémies et Autres Maladies du Sang (GOELAMS). Cancer. 2010 Sep 15;116(18):4299-308. http://www.ncbi.nlm.nih.gov/pubmed?term=Cancer.%20 162 / Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, Lefort S, Marit G, Macro M, Sebban C, Belhadj K, Bordessoule D, Fermé C, Tilly H. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood. 2010 Sep 23;116(12):2040-5. http://bloodjournal.hematologylibrary.org/ 161 / Jardin F, Jais JP, Molina TJ, Parmentier F, Picquenot JM, Ruminy P, Tilly H, Bastard C, Salles GA, Feugier P, Thieblemont C, Gisselbrecht C, de Reynies A, Coiffier B, Haioun C, Leroy K. Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA study. Blood. 2010 Aug 19;116(7):1092-104. http://bloodjournal.hematologylibrary.org/ 160 / Biasoli I, Stamatoullas A, Meignin V, Delmer A, Reman O, Morschhauser F, Coiffier B, Bosly A, Diviné M, Brice P. Nodular, lymphocyte-predominant Hodgkin lymphoma: a long-term study and analysis of transformation to diffuse large B-cell lymphoma in a cohort of 164 patients from the Adult Lymphoma Study Group. Cancer. 2010 Feb 1;116(3):631-9. http://www.ncbi.nlm.nih.gov/pubmed?term=Cancer.%20 159 / Bachy E, Brice P, Delarue R, Brousse N, Haioun C, Le Gouill S, Delmer A, Bordessoule D, Tilly H, Corront B, Allard C, Foussard C, Bosly A, Coiffier B, Gisselbrecht C, Solal-Celigny P, Salles G. Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival--A study from the groupe d'etude des lymphomes de l'adulte. J Clin Oncol. 2010 Feb 10;28(5):822-9. http://jco.ascopubs.org/ 158 / Rolland D, Ribrag V, Haioun C, Ghesquieres H, Jardin F, Bouabdallah R, Franchi P, Briere J, De Kerviler E, Chassagne-Clement C, Raponi M, Houlgatte R, Jais JP, Thieblemont C. Phase II trial and prediction of response of single agent tipifarnib in patients with relapsed/refractory mantle cell lymphoma: a Groupe d'Etude des Lymphomes de l'Adulte trial. Cancer Chemother Pharmacol. 2010 Mar;65(4):781-90. http://www.ncbi.nlm.nih.gov/pubmed?term=Cancer%20C 157 / Ghesquières H, Ferlay C, Sebban C, Perol D, Bosly A, Casasnovas O, Reman O, Coiffier B, Tilly H, Morel P, Van den Neste E, Colin P, Haioun C, Biron P, Blay JY. Long-term follow-up of an age-adapted C5R protocol followed by radiotherapy in 99 newly diagnosed primary CNS lymphomas: a prospective multicentric phase II study of the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Ann Oncol. 2010 Apr;21(4):842-50. http://annonc.oxfordjournals.org 156 / Van der Kaaij MA, Heutte N, van Echten-Arends J, Raemaekers JM, Carde P, Noordijk EM, Fermé C, Thomas J, Eghbali H, Brice P, Bonmati C, Henry-Amar M, Kluin-Nelemans HC. Sperm quality before treatment in patients with early stage Hodgkin's lymphoma enrolled in EORTC-GELA Lymphoma Group trials. Haematologica. 2009 Dec;94(12):1691-7. http://www.haematologica.org/ 155 / Heutte N, Flechtner HH, Mounier N, Mellink WA, Meerwaldt JH, Eghbali H, van't Veer MB, Noordijk EM, Kluin-Nelemans JC, Lampka E, Thomas J, Lugtenburg PJ, Viterbo L, Carde P, Hagenbeek A, van der Maazen RW, Smit WG, Brice P, van Marwijk Kooy M, Baars JW, Poortmans P, Tirelli U, Leeksma OC, Tomsic R, Feugier P, Salles G, Gabarre J, Kersten MJ, Van Den Neste E, Creemers GJ, Gaillard I, Meijnders P, Tertian G, Reman O, Muller HP, Troncy J, Blanc M, Schroyens W, Voogt PJ, Wijermans P, Rieux C, Fermé C, Henry-Amar M; EORTC-GELA H8 Trial Group. Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trial. Lancet Oncol. 2009 Dec;10(12):1160-70. http://www.thelancet.com 154 / Copie-Bergman C, Gaulard P, Leroy K, Briere J, Baia M, Jais JP, Salles GA, Berger F, Haioun C, Tilly H, Emile JF, Banham AH, Mounier N, Gisselbrecht C, Feugier P, Coiffier B, Molina TJ. Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study. J Clin Oncol. 2009 Nov 20;27(33):5573-9. http://jco.ascopubs.org/ 153 / Thieblemont C, Gisselbrecht C. Second-line treatment paradigms for diffuse large B-cell lymphomas. Curr Oncol Rep. 2009 Sep;11(5):386-93. http://www.springerlink.com/content/1523-3790/ 152 / Ribrag V, Gisselbrecht C, Haioun C, Salles G, Golfier JB, Ertault M, Ferme C, Briere J, Brice P, Mounier N. Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA). Cancer. 2009 Oct 1;115(19):4540-6. http://www.ncbi.nlm.nih.gov 151 / Haioun C, Mounier N, Emile JF, Ranta D, Coiffier B, Tilly H, Récher C, Fermé C, Gabarre J, Herbrecht R, Morchhauser F, Gisselbrecht C. Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma. Ann Oncol. 2009 Dec;20(12):1985-92. http://annonc.oxfordjournals.org/ 150 / Favier O, Heutte N, Stamatoullas-Bastard A, Carde P, Van't Veer MB, Aleman BM, Noordijk EM, Thomas J, Fermé C, Henry-Amar M; European Organization forResearch and Treatment of Cancer (EORTC) Lymphoma Group and the Groupe d'Etudes des Lymphomes de l'Adulte (GELA). Survival after Hodgkin lymphoma: causes of death and excess mortality in patients treated in 8 consecutive trials. Cancer. 2009 Apr 15;115(8):1680-91. http://www.ncbi.nlm.nih.gov/ 149 / Dupuis J, Itti E, Rahmouni A, Hemery F, Gisselbrecht C, Lin C, Copie-Bergman C, Belhadj K, El Gnaoui T, Gaillard I, Kuhnowski F, Meignan M, Haioun C. Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria. Ann Oncol. 2009 Mar;20(3):503-7. http://annonc.oxfordjournals.org/ 148 / De Leval L, Gaulard P. Pathobiology and molecular profiling of peripheral T-cell lymphomas. Hematology Am Soc Hematol Educ Program. 2008:272-9. http://asheducationbook.hematologylibrary.org/ 147 / Hancock BW, Qian W, Linch D, Delchier JC, Smith P, Jakupovic I, Burton C, Souhami R, Wotherspoon A, Copie-Bergman C, Capella C, Traulle C, Levy M, Cortelazzo S, Ferreri AJ, Ambrosetti A, Pinotti G, Martinelli G, Vitolo U, Cavalli F, Gisselbrecht C, Zucca E. Chlorambucil versus observation after anti-Helicobacter therapy in gastric MALT lymphomas: results of the international randomised LY03 trial. Br J Haematol. 2009 Feb;144(3):367-75. 146 / Morschhauser F, Brice P, Fermé C, Diviné M, Salles G, Bouabdallah R, Sebban C, Voillat L, Casasnovas O, Stamatoullas A, Bouabdallah K, André M, Jais JP, Cazals-Hatem D, Gisselbrecht C; GELA/SFGM Study Group. Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin's lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group. J Clin Oncol. 2008 Dec 20;26(36):5980-7. http://jco.ascopubs.org/ 145 / Salles G, Mounier N, de Guibert S, Morschhauser F, Doyen C, Rossi JF, Haioun C, Brice P, Mahé B, Bouabdallah R, Audhuy B, Ferme C, Dartigeas C, Feugier P, Sebban C, Xerri L, Foussard C. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood. 2008 Dec 15;112(13):4824-31. http://bloodjournal.hematologylibrary.org/ 144 / Jais JP, Haioun C, Molina TJ, Rickman DS, de Reynies A, Berger F, Gisselbrecht C, Brière J, Reyes F, Gaulard P, Feugier P, Labouyrie E, Tilly H, Bastard C, Coiffier B, Salles G, Leroy K; Groupe d'Etude des Lymphomes de l'Adulte. The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab. Leukemia. 2008 Oct;22(10):1917-24. http://www.nature.com/leu/index.html 143 / Sebban C, Brice P, Delarue R, Haioun C, Souleau B, Mounier N, Brousse N, Feugier P, Tilly H, Solal-Céligny P, Coiffier B. Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study. J Clin Oncol. 2008 Jul 20;26(21):3614-20. http://jco.ascopubs.org/ 142 / Biasoli I, Franchi-Rezgui P, Sibon D, Brière J, de Kerviler E, Thieblemont C, Levy V, Gisselbrecht C, Brice P. Analysis of factors influencing inclusion of 102 patients with stage III/IV Hodgkin's lymphoma in a randomized trial for first-line chemotherapy. Ann Oncol. 2008 Nov;19(11):1915-20. http://annonc.oxfordjournals.org 141 / Coiffier B, Altman A, Pui CH, Younes A, Cairo MS. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol. 2008 Jun 1;26(16):2767-78. http://jco.ascopubs.org/ 140 / Mourad N, Mounier N, Brière J, Raffoux E, Delmer A, Feller A, Meijer CJ, Emile JF, Bouabdallah R, Bosly A, Diebold J, Haioun C, Coiffier B, Gisselbrecht C, Gaulard P; Groupe d'Etude des Lymphomes de l'Adulte. Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. Blood. 2008 May 1;111(9):4463-70. http://bloodjournal.hematologylibrary.org/ 139 / Coiffier B, Tilly H. Dose dance in lymphomas. Lancet Oncol. 2008 Feb;9(2):84-6. http://www.thelancet.com 138 / Morel P, Gaulard P, Gisselbrecht C, Ferme C, Salles G, Tilly H, Brière J, Copin MC, Lederlin P, Hermine O, Theate I, Haioun C, Mounier N; Groupe d'Etude des Lymphomes de l'Adulte. Autologous stem-cell transplantation as consolidation therapy for diffuse large B-cell lymphoma patients with overexpression of bcl-2 protein. Results of the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trial LNH98-B2. Ann Oncol. 2008 Mar;19(3):560-5. 137 / Canioni D, Salles G, Mounier N, Brousse N, Keuppens M, Morchhauser F, Lamy T, Sonet A, Rousselet MC, Foussard C, Xerri L. High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. J Clin Oncol. 2008 Jan 20;26(3):440-6. 136 / Fermé C, Eghbali H, Meerwaldt JH, Rieux C, Bosq J, Berger F, Girinsky T, Brice P, van't Veer MB, Walewski JA, Lederlin P, Tirelli U, Carde P, Van den Neste E, Gyan E, Monconduit M, Diviné M, Raemaekers JM, Salles G, Noordijk EM, Creemers GJ, Gabarre J, Hagenbeek A, Reman O, Blanc M, Thomas J, Vié B, Kluin-Nelemans JC, Viseu F, Baars JW, Poortmans P, Lugtenburg PJ, Carrie C, Jaubert J, Henry-Amar M; EORTC-GELA H8 Trial. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med. 2007 Nov 8;357(19):1916-27. http://www.nejm.org 135 / Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC, Pfreundschuh M, Reiser M, Metzner B, Einsele H, Peter N, Jung W, Wörmann B, Ludwig WD, Dührsen U, Eimermacher H, Wandt H, Hasford J, Hiddemann W, Unterhalt M; German Low Grade Lymphoma Study Group (GLSG); European Mantle Cell Lymphoma Network. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008 Jan 15;111(2):558-65. http://bloodjournal.hematologylibrary.org 134 / Dupuis J, Gaulard P, Hemery F, Itti E, Gisselbrecht C, Rahmouni A, Copie-Bergman C, Brière J, El Gnaoui T, Gaillard I, Meignan M, Haioun C. Respective prognostic values of germinal center phenotype and early (18)fluorodeoxyglucose-positron emission tomography scanning in previously untreated patients with diffuse large B-cell lymphoma. Haematologica. 2007 Jun;92(6):778-83. http://www.haematologica.org 133 / Van der Kaaij MA, Heutte N, Le Stang N, Raemaekers JM, Simons AH, Carde P, Noordijk EM, Fermé C, Thomas J, Eghbali H, Kluin-Nelemans HC, Henry-Amar M; European Organisation for Research and Treatment of Cancer: EORTC Lymphoma Group; Groupe d'Etude des Lymphomes de l'Adulte. Gonadal function in males after chemotherapy for early-stage Hodgkin's lymphoma treated in four subsequent trials by the European Organisation for Research and Treatment of Cancer: EORTC Lymphoma Group and the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2007 Jul1;25(19):2825-32 http://jco.ascopubs.org 132 / Thieblemont C, Coiffier B. Lymphoma in older patients. J Clin Oncol. 2007 May 10;25(14):1916-23. http://jco.ascopubs.org/ 131 / Fermé C, Brice P, Michallet AS, Lederlin P, Diviné M, Casasnovas O, Devidas A, Anglaret B, Cazals-Hatem D, Mounier N; Groupe d'Etudes des Lymphomes de L'adulte. A weekly regimen with dose escalation of doxorubicin for patients with advanced Hodgkin's lymphoma: results of a phase II study of the Groupe d'Etudes des Lymphomes de l'Adulte (GELA). Leuk Lymphoma. 2007 Apr;48(4):691-8. 130 / Casasnovas RO, Mounier N, Brice P, Divine M, Morschhauser F, Gabarre J, Blay JY, Voillat L, Lederlin P, Stamatoullas A, Bienvenu J, Guiguet M, Intrator L, Grandjean M, Brière J, Ferme C, Salles G; Groupe d'Etude des Lymphomes de l'Adulte. Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin's lymphoma: a study from the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2007 May 1;25(13):1732-40. http://jco.ascopubs.org/ 129 / De Jong D, Rosenwald A, Chhanabhai M, Gaulard P, Klapper W, Lee A, Sander B, Thorns C, Campo E, Molina T, Norton A, Hagenbeek A, Horning S, Lister A, Raemaekers J, Gascoyne RD, Salles G, Weller E; Lunenburg Lymphoma Biomarker Consortium. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications--a study from the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol. 2007 Mar 1;25(7):805-12. http://jco.ascopubs.org/ 128 / Plonquet A, Haioun C, Jais JP, Debard AL, Salles G, Bene MC, Feugier P, Rabian C, Casasnovas O, Labalette M, Kuhlein E, Farcet JP, Emile JF, Gisselbrecht C, Delfau-Larue MH; Groupe d'étude des lymphomes de l'adulte. Peripheral blood natural killer cell count is associated with clinical outcome in patients with aaIPI 2-3 diffuse large B-cell lymphoma. Ann Oncol. 2007 Jul;18(7):1209-15. Epub 2007 May 12. http://www.ncbi.nlm.nih.gov 127 / Mounier N, Spina M, Gisselbrecht C. Modern management of non-Hodgkin lymphoma in HIV-infected patients. Br J Haematol. 2007 Mar;136(5):685-98. Epub 2006 Dec 1. http://www.ncbi.nlm.nih.gov 126 / Fermé C, Brice P, Michallet AS, Lederlin P, Diviné M, Casasnovas O, Devidas A, Anglaret B, Cazals-Hatem D, Mounier N; Groupe d'Etudes des Lymphomes de L'adulte. A weekly regimen with dose escalation of doxorubicin for patients with advanced Hodgkin's lymphoma: results of a phase II study of the Groupe d'Etudes des Lymphomes de l'Adulte (GELA). Leuk Lymphoma. 2007 Apr;48(4):691-8.ng http://www.ncbi.nlm.nih.gov 125 / Levy M, Copie-Bergman C, Traulle C, Lavergne-Slove A, Brousse N, Flejou JF, de Mascarel A, Hemery F, Gaulard P, Delchier JC; Groupe d'Etude des Lymphomes de l'Adulte (GELA). Conservative treatment of primary gastric low-grade B-cell lymphoma of mucosa-associated lymphoid tissue: predictive factors of response and outcome. 1: Am J Gastroenterol. 2002 Feb;97(2):292-7 http://www.ncbi.nlm.nih.gov 124 / Diviné M, Casassus P, Koscielny S, Bosq J, Sebban C, Le Maignan C, Stamattoulas A, Dupriez B, Raphaël M, Pico JL, Ribrag V; GELA; GOELAMS. Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol Ann Oncol. 2005 Dec;16(12):1928-35. Epub 2005 Nov 10. http://www.ncbi.nlm.nih.gov 123 / de Leval L, Rickman DS, Thielen C, Reynies A, Huang YL, Delsol G, Lamant L, Leroy K, Brière J, Molina T, Berger F, Gisselbrecht C, Xerri L, Gaulard P. The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood. 2007 Jun 1;109(11):4952-63. Epub 2007 Feb 6 http://www.ncbi.nlm.nih.gov 122 / Coiffier B. Rituximab therapy in malignant lymphoma. Oncogene. 2007 May 28;26(25):3603-13 http://www.ncbi.nlm.nih.gov 121 / Thieblemont C, Coiffier B. Lymphoma in older patients. J Clin Oncol. 2007 May 10;25(14):1916-23 http://www.ncbi.nlm.nih.gov 120 / Bonnet C, Fillet G, Mounier N, Ganem G, Molina TJ, Thiéblemont C, Fermé C, Quesnel B, Martin C, Gisselbrecht C, Tilly H, Reyes F; Groupe d'Etude des Lymphomes de l'Adulte. CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2007 Mar 1;25(7):787-92. Epub 2007 Jan 16. http://www.ncbi.nlm.nih.gov 119 / Lamant L, de Reyniès A, Duplantier MM, Rickman DS, Sabourdy F, Giuriato S, Brugières L, Gaulard P, Espinos E, Delsol G. Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes. Blood. 2007 Mar 1;109(5):2156-64. Epub 2006 Oct 31. http://www.ncbi.nlm.nih.gov 118 / Coiffier B. Rituximab and CHOP-like chemotherapy in good-prognosis diffuse large-B-cell lymphoma. Nat Clin Pract Oncol. 2006 Nov;3(11):594-5. No abstract available. http://www.ncbi.nlm.nih.gov 117 / Coiffier B. Standard treatment of advanced-stage diffuse large B-cell lymphoma. Semin Hematol. 2006 Oct;43(4):213-20 http://www.ncbi.nlm.nih.gov 116 / Bossard C, Belhadj K, Reyes F, Martin-Garcia N, Berger F, Kummer JA, Briere J, Baglin AC, Cheze S, Bosq J, Ribrag V, Gisselbrecht C, Mounier N, Gaulard P. Departement de Pathologie et Inserm U617, Hopital Henri Mondor, France. Expression of the granzyme B inhibitor PI9 predicts outcome in nasal NK/T-cell lymphoma : results of a Western series of 48 patients treated with first-line polychemotherapy within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. Blood. 2006 Oct 31; http://www.ncbi.nlm.nih.gov 115 / Coiffier B. Treatment of non-Hodgkin's lymphoma: a look over the past decade. Clin Lymphoma Myeloma. 2006 Oct;7 Suppl 1:S7-13 http://www.ncbi.nlm.nih.gov 114 / Sebban C, Mounier N, Brousse N, Belanger C, Brice P, Haioun C, Tilly H, Feugier P, Bouabdallah R, Doyen C, Salles G, Coiffier B. Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood. 2006 Oct 15;108(8):2540-4. Epub 2006 Jul 11. 113 / Dupuis J, Emile JF, Mounier N, Gisselbrecht C, Martin-Garcia N, Petrella T, Bouabdallah R, Berger F, Delmer A, Coiffier B, Reyes F, Gaulard P. Prognostic significance of Epstein-Barr virus in nodal peripheral T-cell lymphoma, unspecified: A Goupe d' Eude des Lmphomes de l' Adulte (GELA) study. Blood. 2006 Aug 10; [Epub ahead of print] 112 / Ferme C, Mounier N, Casasnovas O, Brice P, Divine M, Sonet A, Bouafia F, Bastard-Stamatoullas A, Bordessoule D, Voillat L, Reman O, Blanc M, Gisselbrecht C; Groupe d'Etude des Lymphomes de l'Adulte. Long-term results and competing risk analysis of the H89 trial in patients with advanced-stage Hodgkin lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood. 2006 Jun 15;107(12):4636-42. Epub 2006 Feb 14. 111 / Hagberg H, Gisselbrecht C; CORAL study group. Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL study. Ann Oncol. 2006 May;17 Suppl 4:iv31-2. http://www.ncbi.nlm.nih.gov 110 / Mounier N, Spina M, Gabarre J, Raphael M, Rizzardini G, Golfier JB, Vaccher E, Carbone A, Coiffier B, Chichino G, Bosly A, Tirelli U, Gisselbrecht C. AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy. Blood. 2006 May 15;107(10):3832-40. Epub 2006 Jan 12. 109 / Mounier N, Briere J, Gisselbrecht C, Reyes F, Gaulard P, Coiffier B; Groupe d'Etude des Lymphomes de l'Adulte. Estimating the impact of rituximab on bcl-2-associated resistance to CHOP in elderly patients with diffuse large B-cell lymphoma. Haematologica. 2006 May;91(5):715-6. 108 / Hagberg H, Gisselbrecht C; CORAL study group. Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL study. Ann Oncol. 2006 May;17 Suppl 4:iv31-2. 107 / Gisselbrecht C, Mounier N. Managing large cell lymphoma. Ann Oncol. 2006 May;17 Suppl 4:iv8-11. 106 / Mounier N, Briere J, Gisselbrecht C, Reyes F, Gaulard P, Coiffier B. Estimating the impact of rituximab on bcl-2-associated resistance to CHOP in elderly patients with diffuse large B-cell lymphoma. Haematologica. 2006 Apr 3; [Epub ahead of print] 105 / Coiffier B. Monoclonal antibody as therapy for malignant lymphomas. C R Biol. 2006 Apr;329(4):241-54. Epub 2006 Mar 20. Review. 104 / Ballester B, Ramuz O, Gisselbrecht C, Doucet G, Loi L, Loriod B, Bertucci F, Bouabdallah R, Devilard E, Carbuccia N, Mozziconacci MJ, Birnbaum D, Brousset P, Berger F, Salles G, Briere J, Houlgatte R, Gaulard P, Xerri L. Gene expression profiling identifies molecular subgroups among nodal peripheral T-cell lymphomas. Oncogene. 2006 Mar 9;25(10):1560-70. 103 / Besson C, Canioni D, Lepage E, Pol S, Morel P, Lederlin P, Van Hoof A, Tilly H, Gaulard P, Coiffier B, Gisselbrecht C, Brousse N, Reyes F, Hermine O; Groupe d'Etude des Lymphomes de l'Adulte Programs. Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98 Groupe d'Etude des Lymphomes de l'Adulte programs. J Clin Oncol. 2006 Feb 20;24(6):953-60. Epub 2006 Jan 17. 102 / Meignan M, Haioun C, Itti E, Rahmouni A, Reyes F. Value of [18F]fluorodeoxyglucose-positron emission tomography in managing patients with aggressive non-Hodgkin's lymphoma. Clin Lymphoma Myeloma. 2006 Jan;6(4):306-13. Review. 101 / Nicolas Mounier, Michele Spina, Jean Gabarre, Martine Raphael, Giuliano Rizzardini, Jean-Baptiste Golfier, Emanuela Vaccher, Antonino Carbone, Bertrand Coiffier, Guido Chichino, Andre Bosly, Umberto Tirelli, and Christian Gisselbrecht. AIDS-related non-Hodgkin's lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy. Blood First Edition Paper, prepublished online January 12, 2006; DOI 10.1182/blood-2005-09-3600. http://www.bloodjournal.org 100 / Ruiz-Soto R, Sergent G, Gisselbrecht C, Larghero J, Ertault M, Hennequin C, Manson J, de Kerviler E, Briere J, Mounier N. Estimating late adverse events using competing risks after autologous stem-cell transplantation in aggressive non-Hodgkin lymphoma patients. Cancer. 2005 Dec 15;104(12):2735-42. 99 / Haioun C, Itti E, Rahmouni A, Brice P, Rain JD, Belhadj K, Gaulard P, Garderet L, Lepage E, Reyes F, Meignan M. [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood. 2005 Aug 15;106(4):1376-81. Epub 2005 Apr 28. 98 / Gisselbrecht C, Mounier N, Andre M, Casanovas O, Reman O, Sebban C, Divine M, Brice P, Briere J, Hennequin C, Ferme C. How to define intermediate stage in Hodgkin's lymphoma ? Eur J Haematol Suppl. 2005 Jul;(66):111-4. 97 / Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferme C, Christian B, Lepage E, Tilly H, Morschhauser F, Gaulard P, Salles G, Bosly A, Gisselbrecht C, Reyes F, Coiffier B. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2005 Jun 20;23(18):4117-26. Epub 2005 May 2. 96 / Coiffier B, Reyes F; Groupe d'Etude des Lymphomes de l'Adulte. Best treatment of aggressive non-Hodgkin's lymphoma: a French perspective. Oncology (Williston Park). 2005 Apr;19(4 Suppl 1):7-15. Review. 95 / Reyes F, Lepage E, Ganem G, Molina TJ, Brice P, Coiffier B, Morel P, Ferme C, Bosly A, Lederlin P, Laurent G, Tilly H; Groupe d'Etude des Lymphomes de l'Adulte (GELA). ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med. 2005 Mar 24;352(12):1197-205. http://www.ncbi.nlm.nih.gov 94 / Fabiani B, Delmer A, Lepage E, Guettier C, Petrella T, Briere J, Penny AM, Copin MC, Diebold J, Reyes F, Gaulard P, Molina TJ; Groupe d'Etudes des Lymphomes de l'Adulte. Departement de Pathologie, Hopital Saint-Antoine, AP-HP, Paris, France. CD10 expression in diffuse large B-cell lymphomas does not influence survival. Virchows Arch. 2004 Dec;445(6):545-51. Epub 2004 Oct 27 http://www.ncbi.nlm.nih.gov 93 / Mounier N, Gisselbrecht C, Briere J, Haioun C, Feugier P, Offner F, Recher C, Stamatoullas A, Morschhauser F, Macro M, Thieblemont C, Sonet A, Fabiani B, Reyes F; Groupe d'Etude des Lymphomes de l'Adulte. Hopital Saint Louis, AP-HP, Paris, France. nicolas.mounier@sls.ap-hop-paris.fr All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: a matched-control analysis by the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Ann Oncol. 2004 Dec;15(12):1790-7. http://www.ncbi.nlm.nih.gov 92 / S Camilleri-Broët1,2, N Mounier3, A Delmer4, J Brière5, O Casasnovas6, L Cassard2, P Gaulard7, B Christian8, B Coiffier9 and C Sautès-Fridman2 FcRIIB expression in diffuse large B-cell lymphomas does not alter the response to CHOP+rituximab (R-CHOP) Leukemia. 2004 Dec;18(12):2038-40 http://www.nature.com 91 / Solal-Celigny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, Au WY, Bellei M, Brice P, Caballero D, Coiffier B, Conde-Garcia E, Doyen C, Federico M, Fisher RI, Garcia-Conde JF, Guglielmi C, Hagenbeek A, Haioun C, LeBlanc M, Lister AT, Lopez-Guillermo A, McLaughlin P, Milpied N, Morel P, Mounier N, Proctor SJ, Rohatiner A, Smith P, Soubeyran P, Tilly H, Vitolo U, Zinzani PL, Zucca E, Montserrat E. Follicular lymphoma international prognostic index. Blood. 2004 Sep 1;104(5):1258-65. Epub 2004 May 4. 90 / Mounier N, Gisselbrecht C, Briere J, Haioun C, Feugier P, Offner F, Recher C, Stamatoullas A, Morschhauser F, Macro M, Thieblemont C, Sonet A, Fabiani B, Reyes F; Groupe d'Etude des Lymphomes de l'Adulte. Service d'Onco-Hematologie, INSERM ERM0220, Hopital Saint Louis, AP-MP, 1 Avenue Claude Vellefaux, 75010 Paris, France. nicolas.mounier@sls.ap-hop-paris.fr Prognostic factors in patients with aggressive non-Hodgkin's lymphoma treated by front-line autotransplantation after complete remission: a cohort study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2004 Jul 15;22(14):2826-34. http://www.ncbi.nlm.nih.gov 89 / Binn M, Ruskone-Fourmestraux A, Lepage E, Haioun C, Delmer A, Aegerter P, Lavergne A, Guettier C, Delchier JC. Hopital Henri Mondor, Gastroenterologie, Creteil, Val de Marne, France. Surgical resection plus chemotherapy versus chemotherapy alone: comparison of two strategies to treat diffuse large B-cell gastric lymphoma. Ann Oncol. 2003 Dec;14(12):1751-7. http://www.ncbi.nlm.nih.gov 88 / Bertrand Coiffier, Nicolas Mounier, Serge Bologna, Christophe Fermé, Hervé Tilly, Anne Sonet, Bernard Christian, Olivier Casasnovas, Eric Jourdan, Karim Belhadj, Raoul Herbrecht From the Centre Hospitalier Lyon-Sud, Pierre-Bénite; Hôpital Saint-Louis, Paris; Centre Hospitalier Universitaire de Brabois, Vandoeuvre les Nancy; Institut Gustave Roussy, Villejuif; Centre Becquerel, Rouen; Hôpital Bon Secours, Metz; Centre Hospitalier du Bocage, Dijon; Centre Hospitalier de Nîmes, Nîmes; Hôpital Henri Mondor, Créteil; Hôpital de Hautepierre, Strasbourg, France; and Université Catholique de Louvain-Mont Godinne, Yvoir, Belgium. Efficacy and Safety of Rasburicase (recombinant urate oxidase) for the Prevention and Treatment of Hyperuricemia During Induction Chemotherapy of Aggressive Non-Hodgkin’s Lymphoma: Results of the GRAAL1 (Groupe d’Etude des Lymphomes de l’Adulte Trial on Rasburicase Activity in Adult Lymphoma) Study Journal of Clinical Oncology, Vol 21, Issue 23 (December), 2003: 4402-4406 http://www.jco.org 87 / Marc P Andre*, Nicolas Mounier, Xavier Leleu, Anne Sonet, Pauline Brice, Michel Henry-Amar, Herve Tilly, Bertrand Coiffier, Andre Bosly, Pierre Morel, Corinne Haioun, Philippe Gaulard, Felix Reyes, and Christian Gisselbrecht Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen. A GELA cohort study on 2837 patients Blood First Edition Paper, prepublished online October 23, 2003; DOI 10.1182/blood-2003-04-1124. http://www.bloodjournal.org 86 / Gisselbrecht C, Mounier N, Ferme C, Brice P. Ifosfamide salvage treatment before autologous stem cell transplantation in patients with refractory and relapsed Hodgkin's lymphoma: a GELA experience. Ann Oncol. 2003;14 Suppl 1:i39-41 http://annonc.oupjournals.org 85 / P. Feugier1,*, J. M. Virion2, H. Tilly3, C. Haioun4, G. Marit5, M. Macro6, D. Bordessoule7, C. Recher8, M. Blanc9, T. Molina10, P. Lederlin1 and B. Coiffier11 1 Service Hématologie, 2 Service Informatique Médicale, Hôpitaux de Brabois, Nancy; 3 Centre Henri Becquerel, Rouen; 4 Service Hématologie, Hôpital Henri Mondor, AP-HP, Créteil; 5 Service Hématologie, Centre Hospitalier Universitaire, Bordeaux; 6 Service Hématologie, Centre Hospitalier Universitaire, Caen; 7 Service Hématologie, Centre Hospitalier Universitaire, Limoges; 8 Service Hématologie, Centre Hospitalier Universitaire, Toulouse; 9 Service Hématologie, Centre Hospitalier, Chambéry; 10 Service Anatomo-Pathologie, Hôtel Dieu, AP-HP, Paris; 11 Service Hématologie, Hospices Civils, Lyon, France Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. Annals of Oncology 15:129-133, 2004 http://annonc.oupjournals.org 84 / Tilly H, Lepage E, Coiffier B, Blanc M, Herbrecht R, Bosly A, Attal M, Fillet G, Guettier C, Molina TJ, Gisselbrecht C, Reyes F. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin's lymphoma. Blood. 2003 Aug 14 [Epub ahead of print]. http://www.ncbi.nlm.nih.gov 83 / Damaj G, Verkarre V, Delmer A, Solal-Celigny P, Yakoub-Agha I, Cellier C, Maurschhauser F, Bouabdallah R, Leblond V, Lefrere F, Bouscary D, Audouin J, Coiffier B, Varet B, Molina T, Brousse N, Hermine O. Primary follicular lymphoma of the gastrointestinal tract: a study of 25 cases and a literature review. Annalq of Oncology. 2003 Apr;14(4):623-9. http://www.ncbi.nlm.nih.gov 82 / R. Bouabdallah, N. Mounier, C. Guettier, T. Molina, V. Ribrag, C. Thieblemont, A. Sonet, A. Delmer, K. Belhadj, P. Gaulard, C. Gisselbrecht, L. Xerri. T-Cell/Histiocyte-Rich Large B-Cell Lymphomas and Classical Diffuse Large B-Cell Lymphomas Have Similar Outcome After Chemotherapy: A Matched-Control Analysis Journal of Clinical Oncology, Vol 21, Issue 7 (April), 2003: 1271-1277 http://www.jco.org 81 / Mounier N, Briere J, Gisselbrecht C, Emile JF, Lederlin P, Sebban C, Berger F, Bosly A, Morel P, Tilly H, Bouabdallah R, Reyes F, Gaulard P, Coiffier B. Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood. 2003 Jun 1;101(11):4279-84. Epub 2003 Feb 06. http://www.ncbi.nlm.nih.gov 80 / Lome-Maldonado C, Canioni D, Hermine O, Delabesse E, Damotte D, Raffoux E, Gaulard P, Macintyre E, Brousse N; The French Groupe d'Etude des Lymphomes de l'Adulte (GELA). Angio-immunoblastic T cell lymphoma (AILD-TL) rich in large B cells and associated with Epstein-Barr virus infection. A different subtype of AILD-TL ? Leukemia 2002 Oct;16(10):2134-41 http://www.ncbi.nlm.nih.gov 79 / Theate I,Michaux L,Dardenne S,Guiot Y,Brie`re J,Emile J, Fabiani FB,Detry R,Gaulard. Epstein –Barr virus-associated lymphoproliferative disease occurring in a patient with sarcoidosis treated by methotrexate and methylprednisolone. Eur J Haematol 2002:69:248 –253.Blackwell Munksgaard 2002. http://membres.gela.org 78 / Pauline Brice, Corinne Haioun, Marc André, and Christian Gisselbrecht, for the Groupe d'Etude des Lymphomes de l'Adulte Pregnancies after high-dose chemotherapy and autologous stem cell transplantation in aggressive lymphomas Blood, 15 July 2002, Vol. 100, No. 2, pp. 736-736 http://www.bloodjournal.org 77 / Leroy K, Haioun C, Lepage E, Le Metayer N, Berger F, Labouyrie E, Meignin V, Petit B, Bastard C, Salles G, Gisselbrecht C, Reyes F, Gaulard P; Groupe d'Etude des Lymphomes de l'Adulte. p53 gene mutations are associated with poor survival in low and low-intermediate risk diffuse large B-cell lymphomas. Ann Oncol. 2002 Jul;13(7):1108-15 http://www.ncbi.nlm.nih.gov 76 / Ferme C, Mounier N, Divine M; Groupe d'Etudes des Lymphomes de l'Adulte. Current clinical trials for the treatment of adult advanced-stage Hodgkin's disease: GELA experiences. Groupe d'Etudes des Lymphomes de l'Adulte. Ann Oncol 2002;13 Suppl 1:96-7 http://www.ncbi.nlm.nih.gov 75 / Dumontet C, Mounier N, Munck JN, Bosly A, Morschauser F, Simon D, Marit G, Casasnovas O, Reman O, Molina T, Reyes F, Coiffier B. Factors predictive of early death in patients receiving high-dose CHOP (ACVB regimen) for aggressive non-Hodgkin's lymphoma: a GELA study. Br J Haematol 2002 Jul;118(1):210-7 http://www.ncbi.nlm.nih.gov 74 / Bienvenu J, Chvetzoff R, Salles G, Balter C, Tilly H, Herbrecht R, Morel P, Lederlin P, Solal-Celigny P, Audhuy B, Christian B, Gabarre J, Casasnovas O, Marit G, Sebban C, Coiffier B; for the Groupe d'Etude des Lymphomes de l'Adulte. Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment. Hematol J 2001;2(6):378-84 http://www.ncbi.nlm.nih.gov 73 / Gisselbrecht C, Lepage E, Molina T, Quesnel B, Fillet G, Lederlin P, Coiffier B, Tilly H, Gabarre J, Guilmin F, Hermine O, Reyes F; Groupe d'Etude des Lymphomes de l'Adulte. Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J Clin Oncol 2002 May 15;20(10):2472-9 http://www.ncbi.nlm.nih.gov 72 / Bertrand Coiffier, M.D., Eric Lepage, M.D., Ph.D., Josette Brière, M.D., Raoul Herbrecht, M.D., Hervé Tilly, M.D., Reda Bouabdallah, M.D., Pierre Morel, M.D., Eric Van Den Neste, M.D., Gilles Salles, M.D., Ph.D., Philippe Gaulard, M.D., Felix Reyes, M.D., Pierre Lederlin, Pierre Lederlin, Ph.D., and Christian Gisselbrecht, M.D. CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma. The New England Journal of Medicine : Volume 346:235-242 January 24, 2002 Number 4 http://content.nejm.org 71 / By Christophe Fermé, Nicolas Mounier, Marine Divine, Pauline Brice, Aspasia Stamatoullas, Oumedaly Reman, Laurent Voillat, Jérôme Jaubert, Pierre Lederlin, Philippe Colin, Françoise Berger, and Gilles Salles. (pdf) Intensive Salvage Therapy With High-Dose Chemotherapy for Patients With Advanced Hodgkin's Disease in Relapse or Failure After Initial Chemotherapy: Results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial. Journal of Clinical Oncology, Vol 20, No 2 (January 15), 2002: pp 467-475. http://membres.gela.org 70 / Gabarre J, Raphael M, Lepage E, Martin A, Oksenhendler E, Xerri L, Tulliez M, Audouin J, Costello R, Golfier JB, Schlaifer D, Hequet O, Azar N, Katlama C, Gisselbrecht C; Groupe d'Etude des Lymphomes de l'Adulte (GELA). Human immunodeficiency virus-related lymphoma: relation between clinical features and histologic subtypes. Am J Med 2001 Dec 15;111(9):704-11 http://www.ncbi.nlm.nih.gov 69 / Brice P, Colin P, Berger F, de Kerviler E, Divine M, Bouaffia F, Kerneis Y, Blanc M, Lepage E, Ferme C. Advanced Hodgkin disease with large mediastinal involvement can be treated with eight cycles of chemotherapy alone after a major response to six cycles of chemotherapy: a study of 82 patients from the Groupes d'Etudes des Lymphomes de l'Adulte H89 trial. Cancer. 2001 Aug 1;92(3):453-9. http://www.ncbi.nlm.nih.gov 68 / Bosly A, Haioun C, Gisselbrecht C, Reyes F, Coiffier B. High-dose treatment with autologous stem cell transplantation versus sequential chemotherapy: the GELA experience. Eur J Haematol Suppl. 2001 Jul;(64):3-7. http://www.ncbi.nlm.nih.gov 67 / Morel P, Souleau B, Morschhauser F, Duhamel A, Dombret H, Tilly H, Reyes F, Briere J, Coiffier B, Celigny PS, Lepage E, Brousse N; for the GELA (Groupe d'Etude des Lymphomes de l'Adulte). Assessing the Cox model assumption as a statistical tool for classifying lymphomas. Hematol J 2001;2(5):341-51 http://www.ncbi.nlm.nih.gov 66 / Bosly A, Lepage E, Coiffier B, Fillet G, Herbrecht R, Divine M, Dupriez B, Nouvel C, Deconninck E, Tilly H, Bordessoule D, Gaulard P, Gisselbrecht C; for the GELA. Outcome is not improved by the use of alternating chemotherapy in elderly patients with aggressive lymphoma. Hematol J 2001;2(4):279-85 http://www.ncbi.nlm.nih.gov 65 / Cazals-Hatem D, Andre M, Mounier N, Copin MC, Divine M, Berger F, Bosly A, Kerneis Y, Briere J, Quesnel B, Diebold J, Gaulard P. Pathologic and clinical features of 77 Hodgkin's lymphoma patients treated in a lymphoma protocol (LNH87): a GELA study. Am J Surg Pathol. 2001 Mar;25(3):297-306. http://www.ncbi.nlm.nih.gov 64 / Adida C, Haioun C, Gaulard P, Lepage E, Morel P, Briere J, Dombret H, Reyes F, Diebold J, Gisselbrecht C, Salles G, Altieri DC, Molina TJ. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood. 2000 Sep 1;96(5):1921-5. http://www.ncbi.nlm.nih.gov 63 / Haioun C, Lepage E, Gisselbrecht C, Salles G, Coiffier B, Brice P, Bosly A, Morel P, Nouvel C, Tilly H, Lederlin P, Sebban C, Briere J, Gaulard P, Reyes F. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study. J Clin Oncol. 2000 Aug;18(16):3025-30. http://www.ncbi.nlm.nih.gov 62 / Mounier N, Haioun C, Cole BF, Gisselbrecht C, Sebban C, Morel P, Marit G, Bouabdallah R, Ravoet C, Salles G, Reyes F, Lepage E. Quality of life-adjusted survival analysis of high-dose therapy with autologous bone marrow transplantation versus sequential chemotherapy for patients with aggressive lymphoma in first complete remission. Groupe d'Etude les Lymphomes de l'Adulte (GELA). Blood. 2000 Jun 15;95(12):3687-92. http://www.ncbi.nlm.nih.gov 61 / Haioun C, Besson C, Lepage E, Thieblemont C, Simon D, Rose C, Tilly H, Sonet A, Lederlin P, Attal M, Briere J, Reyes F. Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. Groupe d'Etudes des Lymphomes de l'Adulte. Ann Oncol. 2000 Jun;11(6):685-90. http://www.ncbi.nlm.nih.gov 60 / Casasnovas RO, Haioun C, Dumontet C, Gabarre J, Richard B, Lederlin P, Caillot D, Stamatoullas A, Morel P, Quesnel B, Blay JY, Bouabdallah K, Gisselbrecht C. Phase II study of 3-hour infusion of high dose paclitaxel in refractory and relapsed aggressive non-Hodgkin's lymphomas. Groupe d'Etude des Lymphomes de l'Adulte. Haematologica. 2000 May;85(5):502-7. http://www.ncbi.nlm.nih.gov 59 / Ferme C, Sebban C, Hennequin C, Divine M, Lederlin P, Gabarre J, Ferrant A, Caillot D, Bordessoule D, Brice P, Moullet I, Berger F, Lepage E. Comparison of chemotherapy to radiotherapy as consolidation of complete or good partial response after six cycles of chemotherapy for patients with advanced Hodgkin's disease: results of the groupe d'etudes des lymphomes de l'Adulte H89 trial. Blood. 2000 Apr 1;95(7):2246-52. http://www.ncbi.nlm.nih.gov 58 / Tilly H, Mounier N, Lederlin P, Briere J, Dupriez B, Sebban C, Bosly A, Biron P, Nouvel C, Herbrecht R, Bordessoule D, Coiffier B. Randomized comparison of ACVBP and m-BACOD in the treatment of patients with low-risk aggressive lymphoma: the LNH87-1 study. Groupe d'Etudes des Lymphomes de l'Adulte. J Clin Oncol. 2000 Mar;18(6):1309-15. http://www.ncbi.nlm.nih.gov 57 / Brice P, Divine M, Simon D, Coiffier B, Leblond V, Simon M, Voilat L, Devidas A, Morschhauser F, Rohrlich P, Andre M, Lepage E, Ferme C. Feasibility of tandem autologous stem-cell transplantation (ASCT) in induction failure or very unfavorable (UF) relapse from Hodgkin's disease (HD). SFGM/GELA Study Group. Ann Oncol. 1999 Dec;10(12):1485-8. http://www.ncbi.nlm.nih.gov 56 / Coiffier B, Neidhardt-Berard EM, Tilly H, Belanger C, Bouabdallah R, Haioun C, Brice P, Peaud PY, Pico JL, Janvier M, Solal-Celigny P, Brousse N. Fludarabine alone compared to CHVP plus interferon in elderly patients with follicular lymphoma and adverse prognostic parameters: a GELA study. Groupe d'Etudes des Lymphomes de l'Adulte. Ann Oncol. 1999 Oct;10(10):1191-7. http://www.ncbi.nlm.nih.gov 55 / Andre M, Henry-Amar M, Pico JL, Brice P, Blaise D, Kuentz M, Coiffier B, Colombat P, Cahn JY, Attal M, Fleury J, Milpied N, Nedellec G, Biron P, Tilly H, Jouet JP, Gisselbrecht C. Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure: a case-control study. Societe Francaise de Greffe de Moelle. J Clin Oncol. 1999 Jan;17(1):222-9. http://www.ncbi.nlm.nih.gov 54 / A Bosly, E Lepage, B Coiffier, G Fillet, R Herbrecht, M Diviné, B Dupriez, C Nouvel, E Deconninck, H Tilly, D Bordessoule, Ph Gaulard, C Gisselbrecht. Outcome is not improved with alternating chemotherapy in aggressive lymphoma : a prospective randomized study from the GELA on 810 patients. Hematol. J. 53 / Guglielmi C, Gomez F, Philip T, Hagenbeek A, Martelli M, Sebban C, Milpied N, Bron D, Cahn JY, Somers R, Sonneveld P, Gisselbrecht C, Van Der Lelie H, Chauvin F. Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial. J Clin Oncol. 1998 Oct;16(10):3264-9. http://www.ncbi.nlm.nih.gov 52 / N Mounier, C Gisselbrecht, E Lepage. Treatment of Intermediate grade and high grade non Hodgkin's lymphoma. Letter to the Editor. New Engl. J. Med., 339 : 1475-1476, 1998. 51 / Cole BF, Solal-Celigny P, Gelber RD, Lepage E, Gisselbrecht C, Reyes F, Sebban C, Sugano D, Tendler C, Goldhirsch A. Quality-of-life-adjusted survival analysis of interferon alfa-2b treatment for advanced follicular lymphoma: an aid to clinical decision making. J Clin Oncol. 1998 Jul;16(7):2339-44. http://www.ncbi.nlm.nih.gov 50 / Solal-Celigny P, Lepage E, Brousse N, Tendler CL, Brice P, Haioun C, Gabarre J, Pignon B, Tertian G, Bouabdallah R, Rossi JF, Doyen C, Coiffier B. Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial. J Clin Oncol. 1998 Jul;16(7):2332-8. http://www.ncbi.nlm.nih.gov 49 / Gisselbrecht C, Gaulard P, Lepage E, Coiffier B, Briere J, Haioun C, Cazals-Hatem D, Bosly A, Xerri L, Tilly H, Berger F, Bouhabdallah R, Diebold J. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). Blood. 1998 Jul 1;92(1):76-82. http://www.ncbi.nlm.nih.gov 48 / Mounier N, Morel P, Haioun C, Coiffier B, Tilly H, Chatelain C, Lederlin P, Thyss A, Herbrecht R, Gisselbrecht C, Lepage E. A multivariate analysis of the survival of patients with aggressive lymphoma: variations in the predictive value of prognostic factors during the course of the disease. Groupe d'Etudes des Lymphomes de l'Adulte. Cancer. 1998 May 15;82(10):1952-62. http://www.ncbi.nlm.nih.gov 47 / Brice P, Cazals D, Mounier N, Verola O, Neidhart-Berard AM, Remenieras L, Deconinck E, Doyen C, Hamelsand J, Molina T, Moulonguet I, Gisselbrecht C. Primary cutaneous large-cell lymphoma: analysis of 49 patients included in the LNH87 prospective trial of polychemotherapy for high-grade lymphomas. Groupe d'Etude des Lymphomes de l'Adulte. Leukemia. 1998 Feb;12(2):213-9. http://www.ncbi.nlm.nih.gov 46 / Tilly H, Gaulard P, Lepage E, Dumontet C, Diebold J, Plantier I, Berger F, Symann M, Petrella T, Lederlin P, Briere J. Primary anaplastic large-cell lymphoma in adults: clinical presentation, immunophenotype, and outcome. Blood. 1997 Nov 1;90(9):3727-34. http://www.ncbi.nlm.nih.gov 45 / Ferme C, Bastion Y, Brice P, Lederlin P, Divine M, Gabarre J, Assouline D, Ferrant A, Berger F, Lepage E. Prognosis of patients with advanced Hodgkin's disease: evaluation of four prognostic models using 344 patients included in the Group d'Etudes des Lymphomes de l'Adulte Study. Cancer. 1997 Sep 15;80(6):1124-33. http://www.ncbi.nlm.nih.gov 44 / Bastion Y, Blay JY, Divine M, Brice P, Bordessoule D, Sebban C, Blanc M, Tilly H, Lederlin P, Deconinck E, Salles B, Dumontet C, Briere J, Coiffier B. Elderly patients with aggressive non-Hodgkin's lymphoma: disease presentation, response to treatment, and survival--a Groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 years. J Clin Oncol. 1997 Aug;15(8):2945-53. http://www.ncbi.nlm.nih.gov 43 / Ph. Solal-Céligny, N. Brousse, C. Fermé, C. Gisselbrecht, F. Reyes, B. Coiffier. Lymphomes. Frison Roche ed, Paris, 1997 (3ème édition). 42 / Gisselbrecht C, Haioun C, Lepage E, Bastion Y, Tilly H, Bosly A, Dupriez B, Marit G, Herbrecht R, Deconinck E, Marolleau JP, Yver A, Dabouz-Harrouche F, Coiffier B, Reyes F. Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin's lymphoma: factors influencing chemotherapy administration. Groupe d'Etude des Lymphomes de l'Adulte. Leuk Lymphoma. 1997 Apr;25(3-4):289-300. http://www.ncbi.nlm.nih.gov 41 / Wendum D, Sebban C, Gaulard P, Coiffier B, Tilly H, Cazals D, Boehn A, Casasnovas RO, Bouabdallah R, Jaubert J, Ferrant A, Diebold J, de Mascarel A, Gisselbrecht C. Follicular large-cell lymphoma treated with intensive chemotherapy: an analysis of 89 cases included in the LNH87 trial and comparison with the outcome of diffuse large B-cell lymphoma. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 1997 Apr;15(4):1654-63. http://www.ncbi.nlm.nih.gov 40 / Brice P, Bastion Y, Lepage E, Brousse N, Haioun C, Moreau P, Straetmans N, Tilly H, Tabah I, Solal-Celigny P. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 1997 Mar;15(3):1110-7. http://www.ncbi.nlm.nih.gov 39 / Haioun C, Lepage E, Gisselbrecht C, Bastion Y, Coiffier B, Brice P, Bosly A, Dupriez B, Nouvel C, Tilly H, Lederlin P, Biron P, Briere J, Gaulard P, Reyes F. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87-2. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 1997 Mar;15(3):1131-7. http://www.ncbi.nlm.nih.gov 38 / Guerci A, Lederlin P, Reyes F, Bordessoule D, Sebban C, Tilly H, Kerneis Y, Biron P, Gisselbrecht C, Herbrecht R, Coiffier B. Effect of granulocyte colony-stimulating factor administration in elderly patients with aggressive non-Hodgkin's lymphoma treated with a pirarubicin-combination chemotherapy regimen. Groupe d'Etudes des Lymphomes de l'Adulte. Ann Oncol. 1996 Nov;7(9):966-9. http://www.ncbi.nlm.nih.gov 37 / Brice P, Bastion Y, Divine M, Nedellec G, Ferrant A, Gabarre J, Reman O, Lepage E, Ferme C. Analysis of prognostic factors after the first relapse of Hodgkin's disease in 187 patients. Cancer. 1996 Sep 15;78(6):1293-9. http://www.ncbi.nlm.nih.gov 36 / Cazals-Hatem D, Lepage E, Brice P, Ferrant A, d'Agay MF, Baumelou E, Briere J, Blanc M, Gaulard P, Biron P, Schlaifer D, Diebold J, Audouin J. Primary mediastinal large B-cell lymphoma. A clinicopathologic study of 141 cases compared with 916 nonmediastinal large B-cell lymphomas, a GELA ("Groupe d'Etude des Lymphomes de l'Adulte") study. Am J Surg Pathol. 1996 Jul;20(7):877-88. http://www.ncbi.nlm.nih.gov 35 / Solal-Celigny P, Brice P, Brousse N, Caspard H, Bastion Y, Haioun C, Bosly A, Tilly H, Bordessoule D, Sebban C, Harousseau JL, Morel P, Dupas B, Plassart F, Vasile N, Fort N, Leporrier M. Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: a multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 1996 Feb;14(2):514-9. http://www.ncbi.nlm.nih.gov 34 / Divine M, Lepage E, Briere J, Pautier P, Dupriez B, Lederlin P, Mineur P, Tilly H, Blanc M, Audhuy B, Herbrecht R, Coiffier B, Reyes F. Is the small non-cleaved-cell lymphoma histologic subtype a poor prognostic factor in adult patients? A case-controlled analysis. The Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 1996 Jan;14(1):240-8. http://www.ncbi.nlm.nih.gov 33 / Hermine O, Haioun C, Lepage E, d'Agay MF, Briere J, Lavignac C, Fillet G, Salles G, Marolleau JP, Diebold J, Reyas F, Gaulard P. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood. 1996 Jan 1;87(1):265-72. http://www.ncbi.nlm.nih.gov 32 / Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, Sonneveld P, Gisselbrecht C, Cahn JY, Harousseau JL, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995 Dec 7;333(23):1540-5. http://www.ncbi.nlm.nih.gov 31 / Gabarre J, Lepage E, Thyss A, Tubiana R, Bastion Y, Schlaifer D, Sebban C, Ribrag V, Fereres M, Raphael M, et al. Chemotherapy combined with zidovudine and GM-CSF in human immunodeficiency virus-related non-Hodgkin's lymphoma. Ann Oncol. 1995 Dec;6(10):1025-32. http://www.ncbi.nlm.nih.gov 30 / Bastion Y, Brice P, Haioun C, Sonet A, Salles G, Marolleau JP, Espinouse D, Reyes F, Gisselbrecht C, Coiffier B. Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma. Blood. 1995 Oct 15;86(8):3257-62. http://www.ncbi.nlm.nih.gov 29 / Ferme C, Bastion Y, Lepage E, Berger F, Brice P, Morel P, Gabarre J, Nedellec G, Reman O, Cheron N, et al. The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin's disease. Ann Oncol. 1995 Jul;6(6):543-9. http://www.ncbi.nlm.nih.gov 28 / Haioun C, Lepage E, Gisselbrecht C, Coiffier B, Bosly A, Tilly H, Morel P, Nouvel C, Herbrecht R, D'Agay MF, et al. Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: a study of 464 patients. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 1994 Dec;12(12):2543-51. http://www.ncbi.nlm.nih.gov 27 / Morel P, Dupriez B, Herbrecht R, Bastion Y, Tilly H, Delannoy A, Haioun C, Nouvel C, Bouabdallah K, Baumelou E, et al. Aggressive lymphomas with renal involvement: a study of 48 patients treated with the LNH-84 and LNH-87 regimens. Groupe d'Etude des Lymphomes de l'Adulte. Br J Cancer. 1994 Jul;70(1):154-9. http://www.ncbi.nlm.nih.gov 26 / Raphael MM, Audouin J, Lamine M, Delecluse HJ, Vuillaume M, Lenoir GM, Gisselbrecht C, Lennert K, Diebold J. Immunophenotypic and genotypic analysis of acquired immunodeficiency syndrome-related non-Hodgkin's lymphomas. Correlation with histologic features in 36 cases. French Study Group of Pathology for HIV-Associated Tumors. Am J Clin Pathol. 1994 Jun;101(6):773-82. http://www.ncbi.nlm.nih.gov 25 / C. Gisselbrecht, D. Maraninchi, JL Pico, N. Milpied, B. Coiffier, M. Divine, P. Tiberghien, A. Bosly, 0. Boulat, M. Brandely. Interleukin 2 treatment in lymphoma: A phase Il multicenter study. Blood, vol 83, n'8, p 2081-2085, 1994. 24 / Ph Solal Celigny, N. Brousse, F. Reyes, C. Gisselbrecht, B. Coiffier. eds Non Hodgkin's lymphomas. Lymphomes Non Hodgkiniens. Treatment of low-grade Non Hodgkin's lymphomas : 1993, 317-336 Paris : Frison Roche Childhood Non Hodgkin's lymphomas 1993, 157-160 23 / Solal-Celigny P, Lepage E, Brousse N, Reyes F, Haioun C, Leporrier M, Peuchmaur M, Bosly A, Parlier Y, Brice P, et al. Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d'Etude des Lymphomes de l'Adulte. N Engl J Med. 1993 Nov 25;329(22):1608-14. http://www.ncbi.nlm.nih.gov 22 / MA Shipp, DP Harrington, JR Anderson, JO Armitage, G Bonnadonna, G Brittinger, F Cabanillas, GP Canellos, B Coiffier, JM Connors, RA Cowan, D Growther, SJ Dahlberg, M Engelhard, RI Fisher, C. Gisselbrecht, SJ Horning, E Lepage, TA Lister, JH Meerwaldt, E Montserrat, NI Nissen, MM Oken, BA Peterson, C Tondini, WS Velasquez, BY Yeap A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993 Sep 30;329(14):987-94. http://www.ncbi.nlm.nih.gov 21 / Lepage E, Gisselbrecht C, Haioun C, Sebban C, Tilly H, Bosly A, Morel P, Herbrecht R, Reyes F, Coiffier B. Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: application to LNH-87 protocol. The GELA. (Groupe d'Etude des Lymphomes de l'Adulte). Ann Oncol. 1993 Sep;4(8):651-6. http://www.ncbi.nlm.nih.gov 20 / Gisselbrecht C, Oksenhendler E, Tirelli U, Lepage E, Gabarre J, Farcet JP, Gastaldi R, Coiffier B, Thyss A, Raphael M, et al. Human immunodeficiency virus-related lymphoma treatment with intensive combination chemotherapy. French-Italian Cooperative Group. Am J Med. 1993 Aug;95(2):188-96. http://www.ncbi.nlm.nih.gov 19 / Gisselbrecht C, Bosly A, Lepage E, Reyes F, Philip T, Haioun C, Tilly H, Coiffier B. Autologous hematopoietic stem cell transplantation in intermediate and high grade non-Hodgkin's lymphoma: a review. Ann Oncol. 1993;4 Suppl 1:7-13. Review. http://www.ncbi.nlm.nih.gov 18 / Blay JY, Lasset C, Carrie C, Chauvin F, Coiffier B, Gisselbrecht C, Clavel M, Rebattu P, Brunat-Mentigny M, Philip T, et al. Multivariate analysis of prognostic factors in patients with non HIV-related primary cerebral lymphoma. A proposal for a prognostic scoring. Br J Cancer. 1993 May;67(5):1136-41. http://www.ncbi.nlm.nih.gov 17 / Bosly A, Gisselbrecht C, Coiffier B. Intensive chemotherapy plus hematopoietic stem cells transplantation for relapsing non-Hodgkin's lymphoma: the GELA experience. Nouv Rev Fr Hematol. 1993 Feb;35(1):21-3. Review. http://www.ncbi.nlm.nih.gov 16 / Tirelli U, Errante D, Oksenhendler E, Spina M, Vaccher E, Serraino D, Gastaldi R, Repetto L, Rizzardini G, Carbone A, et al. Prospective study with combined low-dose chemotherapy and zidovudine in 37 patients with poor-prognosis AIDS-related non-Hodgkin's lymphoma. French-Italian Cooperative Study Group. Ann Oncol. 1992 Dec;3(10):843-7. http://www.ncbi.nlm.nih.gov 15 / Bosly A, Coiffier B, Gisselbrecht C, Tilly H, Auzanneau G, Andrien F, Herbrecht R, Legros M, Devaux Y, Jaubert J, et al. Bone marrow transplantation prolongs survival after relapse in aggressive-lymphoma patients treated with the LNH-84 regimen. J Clin Oncol. 1992 Oct;10(10):1615-23. http://www.ncbi.nlm.nih.gov 14 / Emilie D, Coumbaras J, Raphael M, Devergne O, Delecluse HJ, Gisselbrecht C, Michiels JF, Van Damme J, Taga T, Kishimoto T, et al. Interleukin-6 production in high-grade B lymphomas: correlation with the presence of malignant immunoblasts in acquired immunodeficiency syndrome and in human immunodeficiency virus-seronegative patients. Blood. 1992 Jul 15;80(2):498-504. http://www.ncbi.nlm.nih.gov 13 / Morel P, Lepage E, Brice P, Dupriez B, D'Agay MF, Fenaux P, Gosselin B, Bauters F, Gisselbrecht C. Prognosis and treatment of lymphoblastic lymphoma in adults: a report on 80 patients. J Clin Oncol. 1992 Jul;10(7):1078-85. http://www.ncbi.nlm.nih.gov 12 / Salles G, Herbrecht R, Brice P, Sebban C, Tilly H, Lederlin P, Berger F, Coiffier B. Treatment of aggressive primary lymphomas of the digestive system by intensive chemotherapy. Experience of the Study Group on Lymphomas in Adults with the LNH-84 protocol. Ann Gastroenterol Hepatol (Paris). 1992 Jun-Sep;28(4):205-8. French. http://www.ncbi.nlm.nih.gov 11 / Gaulard P, d'Agay MF, Peuchmaur M, Brousse N, Gisselbrecht C, Solal-Celigny P, Diebold J, Mason DY. Expression of the bcl-2 gene product in follicular lymphoma. Am J Pathol. 1992 May;140(5):1089-95. http://www.ncbi.nlm.nih.gov 10 / C. Gisselbrecht, Ph SolalCeligny, N. Brousse, F. Reyes, B. Coiffier. Traitement des lymphomes Non Hodgkiniens de faible malignité. Paris : Frison Roche, 1991, 313331. Lymphomes Non Hodgkiniens. 9 / Coiffier B, Gisselbrecht C, Vose JM, Tilly H, Herbrecht R, Bosly A, Armitage JO. Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes Agressifs. J Clin Oncol. 1991 Feb;9(2):211-9. http://www.ncbi.nlm.nih.gov 8 / Peuchmaur M, Emilie D, Crevon MC, Brousse N, Gaulard P, D'Agay MF, Galanaud P, Solal-Celigny P. Interleukin-2 and interferon-gamma production in follicular lymphomas. Am J Clin Pathol. 1991 Jan;95(1):55-62. http://www.ncbi.nlm.nih.gov 7 / Salles G, Herbrecht R, Tilly H, Berger F, Brousse N, Gisselbrecht C, Coiffier B. Aggressive primary gastrointestinal lymphomas: review of 91 patients treated with the LNH-84 regimen. A study of the Groupe d'Etude des Lymphomes Agressifs. Am J Med. 1991 Jan;90(1):77-84. http://www.ncbi.nlm.nih.gov 6 / Lepage E, Sebban C, Gisselbrecht C, Coiffier B, Harousseau JL, Bryon PA, Boiron M. Treatment of low-grade non-Hodgkin's lymphomas: assessment of doxorubicin in a controlled trial. Hematol Oncol. 1990 Jan-Feb;8(1):31-9. http://www.ncbi.nlm.nih.gov 5 / Coiffier B, Brousse N, Peuchmaur M, Berger F, Gisselbrecht C, Bryon PA, Diebold J. Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. The GELA (Groupe d'Etude des Lymphomes Agressives). Ann Oncol. 1990;1(1):45-50. http://www.ncbi.nlm.nih.gov 4 / MF D'Agay, R. Berger, A. Bernheim, B. Coiffier, Ph. Gaulard, F. Reyes, and M. Peries. Moderator : C. Gisselbrecht. New trends in lymphomas. Nouv. Rev. Fr. Hematol, 139144, 1989. Rev. Fr. Hematol, 139144, 1989. 3 / Coiffier B, Gisselbrecht C, Herbrecht R, Tilly H, Bosly A, Brousse N. LNH-84 regimen : a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. J Clin Oncol. 1989 Aug;7(8):1018-26. http://www.ncbi.nlm.nih.gov 2 / Coiffier B, Lepage E. Prognosis of aggressive lymphomas: a study of five prognostic models with patients included in the LNH-84 regimen. Blood. 1989 Aug 1;74(2):558-64. http://www.ncbi.nlm.nih.gov 1 / Coiffier B, Bosly A, Caligaris-Cappio F, Gisselbrecht C, Patte C, Schaadt M, Symann M. European School of Oncology: management of non-Hodgkin's lymphomas: conclusions of the European School of Oncology Meeting, 1986. Eur J Cancer Clin Oncol. 1987 Nov;23(11):1691-5. Review. No abstract available. http://www.ncbi.nlm.nih.gov